NCT01909934 2025-09-19Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaTakedaPhase 4 Completed50 enrolled 22 charts
NCT01990534 2021-04-09A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaTakedaPhase 4 Completed60 enrolled 21 charts